-
1
-
-
84914173724
-
No evidence of disease activity: Indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis
-
Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther 2014;31: 1134-1154.
-
(2014)
Adv Ther
, vol.31
, pp. 1134-1154
-
-
Nixon, R.1
Bergvall, N.2
Tomic, D.3
Sfikas, N.4
Cutter, G.5
Giovannoni, G.6
-
3
-
-
84860448559
-
Neurofilaments as biomarkers in multiple sclerosis
-
Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012;18:552-556.
-
(2012)
Mult Scler
, vol.18
, pp. 552-556
-
-
Teunissen, C.E.1
Khalil, M.2
-
4
-
-
84884471946
-
A comparative study of CSF neurofilament light and heavy chain protein in MS
-
Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013;19:1597-1603.
-
(2013)
Mult Scler
, vol.19
, pp. 1597-1603
-
-
Kuhle, J.1
Plattner, K.2
Bestwick, J.P.3
-
5
-
-
0036145606
-
Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability
-
Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-139.
-
(2002)
J Neuroimmunol
, vol.122
, pp. 132-139
-
-
Semra, Y.K.1
Seidi, O.A.2
Sharief, M.K.3
-
6
-
-
84904721629
-
Assessing tissue damage in multiple sclerosis: A biomarker approach
-
Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand 2014; 130:81-89.
-
(2014)
Acta Neurol Scand
, vol.130
, pp. 81-89
-
-
Burman, J.1
Zetterberg, H.2
Fransson, M.3
Loskog, A.S.4
Raininko, R.5
Fagius, J.6
-
7
-
-
84928139473
-
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
-
Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015;84:1639-1643.
-
(2015)
Neurology
, vol.84
, pp. 1639-1643
-
-
Kuhle, J.1
Disanto, G.2
Lorscheider, J.3
-
8
-
-
77949904336
-
Neurofilament light as a prognostic marker in multiple sclerosis
-
Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-292.
-
(2010)
Mult Scler
, vol.16
, pp. 287-292
-
-
Salzer, J.1
Svenningsson, A.2
Sundstrom, P.3
-
9
-
-
79551478161
-
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
-
Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69:83-89.
-
(2011)
Ann Neurol
, vol.69
, pp. 83-89
-
-
Gunnarsson, M.1
Malmestrom, C.2
Axelsson, M.3
-
10
-
-
84902186393
-
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
-
Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014;82: 1499-1507.
-
(2014)
Neurology
, vol.82
, pp. 1499-1507
-
-
Romme Christensen, J.1
Ratzer, R.2
Bornsen, L.3
-
11
-
-
84890808806
-
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
-
Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014;20:43-50.
-
(2014)
Mult Scler
, vol.20
, pp. 43-50
-
-
Axelsson, M.1
Malmestrom, C.2
Gunnarsson, M.3
|